Gilead Sciences, Inc. (GILD) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 58 analysts30.7% Below Target
GILD trades 30.7% below Wall Street's consensus target of $161.81.
Current Price$123.76
Average Target$161.81
Target
Current
Low$122.00
Median$165.00
High$180.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth-105.6%
(Declining)
Analyst Spread35.8%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes GILD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 58 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
GILD Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Gilead Sciences, Inc. (GILD) has a Wall Street consensus price target of $161.81, based on estimates from 58 covering analysts. With the stock currently trading at $123.76, this represents a potential upside of +30.7%. The company has a market capitalization of $153.66B.
Analyst price targets range from a low of $122.00 to a high of $180.00, representing a 36% spread in expectations. The median target of $165.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 38 analysts rating the stock as a Buy or Strong Buy,19 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, GILD trades at a trailing P/E of 18.3x. Analysts expect EPS to grow -105.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $150.23, with bear and bull scenarios of $94.64 and $197.94 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+15.2%
Industry Consensus
Avg Forward P/E
15.2x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ABBVAbbVie Inc. | $383.2B | $216.63 | $256.92 | +18.6% | Buy | 15.2x | 41 |
 BMYBristol-Myers Squibb Company | $110.3B | $54.00 | $62.60 | +15.9% | Hold | 8.5x | 41 |
 AMGNAmgen Inc. | $182.2B | $337.60 | $349.33 | +3.5% | Buy | 15.1x | 38 |
 BIIBBiogen Inc. | $29.0B | $196.58 | $218.32 | +11.1% | Buy | 13.5x | 48 |
 REGNRegeneron Pharmaceuticals, Inc. | $63.4B | $609.94 | $836.00 | +37.1% | Buy | 13.1x | 48 |
 VRTXVertex Pharmaceuticals Incorporated | $114.9B | $451.63 | $553.93 | +22.7% | Buy | 23.4x | 56 |
 MRKMerck & Co., Inc. | $281.2B | $113.87 | $131.58 | +15.6% | Buy | 22.2x | 37 |
 PFEPfizer Inc. | $143.5B | $25.22 | $26.75 | +6.1% | Hold | 8.5x | 39 |
 JNJJohnson & Johnson | $550.4B | $228.39 | $251.55 | +10.1% | Buy | 19.7x | 40 |
 INCYIncyte Corporation | $19.6B | $98.22 | $109.80 | +11.8% | Buy | 13.0x | 44 |
GILD — Frequently Asked Questions
Quick answers to the most common questions about buying GILD stock.
What is the GILD stock price target for 2026?
The consensus Wall Street price target for GILD is $161.81, representing 30.7% upside from the current price of $123.76. With 58 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is GILD a buy, sell, or hold?
GILD has a consensus rating of "Buy" based on 58 Wall Street analysts. The rating breakdown is predominantly bullish, with 38 Buy/Strong Buy ratings. The consensus 12-month price target of $161.81 implies 30.7% upside from current levels.
Is GILD stock overvalued or undervalued?
GILD's current price is $123.76 with a consensus target of $161.81 (30.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can GILD stock go?
The most bullish Wall Street analyst has a price target of $180 for GILD, while the most conservative target is $122. The consensus of $161.81 represents the median expectation. Our quantitative valuation model projects a bull case target of $198 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover GILD stock?
GILD is heavily covered by Wall Street, with 58 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 38 have Buy ratings, 19 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GILD stock forecast?
The 12-month GILD stock forecast based on 58 Wall Street analysts shows a consensus price target of $161.81, with estimates ranging from $122 (bear case) to $180 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $150, with bear/bull scenarios of $95/$198.
What is GILD's fair value based on fundamentals?
Our quantitative valuation model calculates GILD's fair value at $150 (base case), with a bear case of $95 and bull case of $198. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
Should I buy GILD stock?
Wall Street analysts are very optimistic on GILD, with a "Buy" consensus rating and $161.81 price target (30.7% upside). 38 of 58 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GILD price targets vary so much?
GILD analyst price targets range from $122 to $180, a 36% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $161.81 consensus represents the middle ground. Our model's $95-$198 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into GILD consensus models and risk factors.
View Analysis
Should I Buy GILD?
Wall Street verdict, signals, and target summaries.
See Verdict
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare